Rationale. is paper describes the rationale and design of the SHEF-CSVD Study, which aims to determine the long-term clinical and radiological course of cerebral small vessel disease (CSVD) and to evaluate haemostatic and haemodynamic prognostic factors of the condition. Design. is single-centre, prospective, non-interventional cohort study will follow 150 consecutive patients with different clinical manifestations of CSVD (lacunar ischaemic stroke, vascular dementia, vascular parkinsonism or spontaneous deep, intracerebral haemorrhage) and 50 age-and sex-matched controls over a period of 24 months. e clinical and radiological course will be evaluated basing on a detailed neurological, neuropsychological and MRI examinations. Haemodynamic (cerebral vasoreactivity, 24 h blood pressure control) and haemostatic factors (markers of endothelial and platelet dysfunction, brachial artery �ow-mediated dilatation test) will be determined. Discussion. e scheduled study will speci�cally address the issue of haemodynamic and haemostatic prognostic factors and their course over time in various clinical manifestations of CSVD. e �ndings may aid the development of prophylactic strategies and individualised treatment plans, which are critical during the early stages of the disease.
Background
Effective therapeutic and preventive strategies in neurological diseases of the elderly are lacking. Cerebral small vessel disease (CSVD) is one of the most important and common vascular diseases of the brain. High morbidity rates are associated with CSVD; this disease leads to recurrent ischaemic and haemorrhagic strokes, gait disturbances, vascular dementia, and vascular parkinsonism [1, 2] . e course and prognosis of the disorder are not well known. Although patients with CSVD may exhibit white-matter lesion burdens on conventional MRIs that are almost identical, they may present clinically with a range of motor and cognitive de�cits that is greatly varied. CSVD is related to vascular risk factors like hypertension, advanced age, and smoking; however, the direct pathophysiological mechanisms of the disease remain unclear [3] . Potential mechanisms include cerebrovascular risk factor-induced ischaemic cerebral changes and other nonspeci�c cerebral processes, such as generalised vascular disease or normal ageing [4] . e pathological components of CSVD probably include increased permeability of the blood-brain-barrier (BBB), enlargement of perivascular spaces, lacunar infarcts, white-matter lesions (WMLs), and microbleeds [5] . CSVD encompasses degenerative alterations in the vessel wall: arteriosclerosis/atherosclerosis, arteriolosclerosis, and lipohyalinosis which are assumed to be pathogenetically linked. Advanced age and chronic hypertension are the most important risk factors for CSVD. ey induce hyperplastic arteriolosclerosis with deposits of �brohyaline material, aneurysmal dilatation, and segmental arterial wall disorganisation of small, perforating intracerebral arteries which become susceptible to either occlusion or rupture leading to lacunar infarcts or spontaneous, deep hemorrhagic strokes, respectively. e reason why some vessel ruptures lead to major haemorrhage while others lead to microhaemorrhage is unknown. Pathological changes of intraparenchymal small arteries and arterioles are thought to represent the underlying vascular cause in combination with �uctuations of systemic blood pressure and altered cerebral blood �ow autoregulation [6] . Lacunar strokes represent the focal manifestation of actually a diffuse abnormality of the small cerebral arterioles resulting in a state of chronic hypoperfusion of the white-matter, eventually resulting in degeneration of myelinated �bres as a consequence of repeated selective oligodendrocyte death. Multiple infarcts may also denote a more generalized phenomenon such as in�ammation, oxidative stress, or disruption in the BBB which can manifest clinically as cognitive decline, dementia, or vascular parkinsonism [7] . Vascular cognitive impairment and vascular parkinsonism are not regular clinical and pathogenetic entities as they overlap with other diagnoses but the majority of patients present widespread microangiopathyrelated cerebral damage [8] . Subcortical vascular cognitive impairment is now recognized to be the commonest form of vascular cognitive impairment, and it is recognized as subcortical vascular dementia in the International Classi�cation of Diseases, 10th revision [9] .
Markers of vascular in�ammation and platelet reactivity are elevated in CSVD� however, their prognostic signi�cance and role in different clinical manifestations of CSVD are not clear [10, 11] . It is unknown whether elevated in�ammatory markers are a consequence of haemostatic disturbances in acute lacunar stroke or if they are secondary to generalised atherothrombosis or increased permeability of the BBB. e role of in�ammation is speculated in vascular dementia whose incidence is in�uenced by the gene polymorphisms of the in�ammatory mediators (interleukin 1, interleukin 6, TNF , toll-like receptor 4, p-selectin, and C-reactive protein), nitric oxide release, and extracellular matrix (matrix metalloproteinases) [12] . Endothelial dysfunction may contribute to breakdown of BBB and impaired vessel reactivity and autoregulation [13] .
Haemodynamic factors are known to play a key role in acute lacunar stroke. While they may predict stroke severity and prognosis, their role in various clinical presentations of CSVD has not been elucidated [14] . Impairments of cerebral autoregulation or vasomotor reactivity may precede and contribute to the onset of clinical dementia and development of WMLs, even in individuals who are asymptomatic, raising important research questions concerning the nature, severity, and causes of impaired cerebral autoregulation in CSVD [15, 16] . e relative importance of haemodynamic versus thromboembolic mechanisms in the pathogenesis of CSVD is difficult to ascertain. It is unknown whether these features provide prognostic information in CSVD that is more robust than the vascular factors traditionally used for this purpose. To date, no standardised prospective trials have been performed to assess the clinical and radiological course of the different manifestations of CSVD with respect to changes in vascular endothelium, thrombocyte function, and haemodynamic parameters.
e object of present study is to describe the long-term clinical and radiological course of most important manifestations of CSVD (lacunar and hemorrhagic stroke, vascular parkinsonism, and dementia) and to evaluate haemostatic and haemodynamic prognostic factors of the condition. Factors and mechanisms contributing towards variable phenotypic (clinical, functional, and neuroradiological) expression of CSVD linking cerebral blood �ow and microvascular in�ammation to the extent of white-matter damage can provide important mechanistic and therapeutic insights. e analysis of patients through a longitudinal study should also contribute to more advanced and conclusive evidence of the CSVD prognosis. e �ndings may aid in the development of prophylactic strategies and individualised treatment plans, which are critical during the early stages of the disease.
In the SHEF-CSVD Study (signi�cance of hemodynamic and hemostatic factors in the course of different manifestations of cerebral small vessel disease) we investigate the role of hemodynamic and hemostatic factors in the course of CSVD prospectively.
To our knowledge, no other prospective cohort studies have been performed to associate these risk factors with different manifestations of CSVD. e research design and protocol of the SHEF-CSVD study are described. (i) aged between 60 and 90 years AND,
(ii) signed informed consent form.
Diagnosis of vascular dementia has been established based on widely used research settings, most sensitive Modi�ed Hachinski Ischemic Scale, and most speci�c NINDS-AIREN set of criteria [22] . Eligible subjects, presenting with acute lacunar ischemic or haemorrhagic stroke, will be included in the study at least 2 weeks following the stroke to avoid acute effects on the outcomes measures.
Exclusion criteria for the study are (i) non-CSVD-related WMLs (e.g., WMLs due to multiple sclerosis, migraine, CADASIL, vasculitis, and Lyme disease),
(ii) large (>1.5 cm) subcortical infarcts or any cortical infarcts, (iii) history of cardioembolic stroke risk factors (e.g., atrial �brillation and valvular heart disease) or carotid or intracranial artery stenosis ≥50% identi�ed via ultrasound [23, 24] , (iv) lacunar stroke treated with thrombolysis or any other previous ischaemic or haemorrhagic stroke, (v) severe neurological de�cits (modi�ed Rankin Scale score ≥ 3 points, indicating at least moderate disability, and/or NIHSS ≥ 10 points), disturbed consciousness (NIHSS 1a ≥1), or severe dementia (MMSE < 12 points), requiring institutional care, (vi) psychiatric disorder interfering with cognitive testing or followup assessment (e.g., alcoholism), (vii) concomitant epilepsy, chronic heart failure (NYHA > II), malignant disease, and/or life expectancy of less than six months, (viii) signi�cant visual and/or hearing impairment, (ix) MRI contraindications, such as claustrophobia, (x) lack of reliable contact with study patients and their relatives during the study.
2.2.
Aim. is single-centre, prospective, noninterventional cohort study will follow 150 consecutive patients with different clinical manifestations of CSVD (lacunar ischaemic stroke, vascular dementia, vascular parkinsonism or spontaneous deep, and intracerebral haemorrhage) and 50 age-and sex-matched controls over a period of 24 months. e study is designed to: primary goals:
(1) assess the long-term clinical and radiological course of CSVD, All neurological, neuropsychological, and radiological assessments will be performed at baseline and at a 24-month followup examination. Baseline and followup assessments will be carried out by the same team of experienced investigators, who will be blinded to the clinical diagnosis of each subject.
e primary outcome measures used in this study will be the observed changes in neurological status, cognitive function, gait/balance, and parkinsonian signs in addition to the progression of WMLs visualised via MRI. Secondary outcome measures that will be used are vascular-induced causes of death and the occurrence of dementia, depression and vascular events.
Study Timeline

Evaluation of Clinical Indicators of CSVD (Baseline and Followup Visits).
It is planned to enroll eligible patients within 12 months of recruitment. e progression of CSVD will be assessed based on �ndings from the neurological, neuropsychological, and radiological examinations performed at the baseline and 24-month followup visits.
Cardiovascular Determinants.
All patients will undergo a clinical evaluation, which includes an interview of past medical history and physical examination. Vascular risk factor pro�les, which include information related to hypertension, diabetes mellitus, coronary artery disease, hypercholesterolemia, peripheral vascular disease, smoking, and alcohol intake, will be recorded for all participants at baseline and followup. Hypertension is de�ned as the mean systolic blood pressure ≥140 mm Hg, mean diastolic blood pressure ≥90 mm Hg, or self-reported use of antihypertensive drugs [25] . Diabetes mellitus is de�ned as a history of diabetes mellitus, fasting plasma glucose levels ≥7.0 mmol/L, or use of oral antidiabetic drugs or insulin [26] . Hyperlipidemia is de�ned as total cholesterol >5.0 mmol/L, low-density lipoprotein cholesterol >3.2 mmol/L, or the self-reported use of lipid-lowering drugs [27] . Tobacco use history will be calculated by multiplying the number of cigarette packs smoked per day by the number of years smoked. Participant height and weight will be measured to calculate body mass indexin kg/m 2 . e use of antiplatelet drugs, blood pressurelowering medication, acetylcholinesterase inhibitors, and/or hypoglycaemic, hypolipaemic, and antiparkinsonian agents throughout the study will be recorded.
Clinical and Neuropsychological Assessments.
Health status as well as the presence and severity of disability will be assessed in all participants by the same two board-certi�ed senior neurologists. e modi�ed Rankin Scale (mRS) will be used to evaluate functional status, and the National Institutes of Health Stroke Scale (NIHSS) will be used to assess neurological impairment. To measure the ability to perform activities of daily living as well as disturbances in movement and gait, the Barthel Scale, the Uni�ed Parkinson Disease Rating Scale (UPDRS), and the Berg Balance Scale will be used [28, 29] .
ese neuropsychological tests were chosen to investigate executive function and other cognitive domains that are typically impaired in CSVD. Assessments of cognitive and executive abilities that have been standardised and psychometrically validated will be utilised. e entire battery of tests includes measures of global cognitive function 
MRI Protocol.
e imaging protocol calls for multiple scan sequences, which include techniques performed at differing repetition and echo times (TR and TE, resp.). e protocol was designed to collect a series of T1-weighted images (TR = 600 ms, TE = 10 ms), T2-weighted images (TR = 5400 ms, TE = 68 ms), fast �uid-attenuation inversion recovery (FLAIR) images (TR = 8000 ms, TE = 120 ms), gradient-recalled echo (GRE) scans (TR = 850 ms, TE = 15 ms), and diffusion-weighted imaging (DWI) sequences (TR = 6000 ms, TE = 105 ms). ese sequences will be performed using a GE Healthcare 1.5 Tesla scanner, and the slice thickness for all images will be set to 5 mm with no intersectional gaps. e presence, number, and location (lobar, deep, or infratentorial) of various types of strokes will be recorded. Deep haemorrhagic strokes are de�ned as being in the late, subacute phase if hyperintense lesions on T1-and T2-weighted images are observed, or as being in the chronic phase if hypointensities are found on T1-and T2-weighted images. Lacunar infarcts are described as focal lesions between 3 and 15 mm in size, visualised as hyperintensities on T2 imaging, hypointense lesions on T1-weighted and hyperintense rim on FLAIR images. Scans from the imaging sequences will be assessed for subcortical and cortical infarcts (lesions ≥ 15 mm in size), microbleeds (focal areas < 5 mm in size, hypointense on GRE, and not representative of calci�ca-tions within the blood vessels), and enlarged Virchow Robin spaces (dilated perivascular spaces that appear hypointense on T1 or punctate or linear hyperintensities on T2 images) [41, 42] . DWI sequences will be used to detect and record acute and subacute infarcts.
White-matter lesions, which are visualised on T2 and PD�FLAIR images as ill-de�ned hyperintensities ≥5 mm, will be evaluated. e ARWMC Scale and the Fazekas Scale are used to quantify the severity of these lesions because they take the location, pattern, and extension of WMLs into account (Table 2 ) [43] [44] [45] . e ARWMC Scale scores �ve different regions in the right and le hemispheres separately: (1) the frontal area, (2) the parietooccipital area, (3) the temporal area, (4) the infratentorial area, and (5) the basal ganglia. e Fazekas Scale will be used to assess the presence of periventricular hyperintensities (PVH), observed as T2 and FLAIR hyperintense signal abnormalities in the periventricular areas, as well as deep WMLs. Global cerebral atrophy (GCA) will be assessed using FLAIR images and the GCA Scale, on which scores range from 0 to 3 [46] . All MRI scans will be obtained using the same scanner (GE Healthcare 1.5 Tesla scanner).
e complete set of baseline MRI variables of interest, which includes quantitative assessments of white-matter lesions, qualitative assessment of brain infarction, microbleeds, and cortical atrophy, will be compared with those obtained from followup MRI scans. Baseline and followup scans will be read independently and used to calculate change scores over time.
Haemodynamic and Haemostatic Indicators (Baseline Visit).
Cerebral hemodynamic status is determined by assessing cerebral vasomotor reactivity (VMR) which provides information related to cerebral autoregulation and pulsatility indices (PIs)� these indices re�ect collateral circulation and increased vascular resistance that result from CSVD [47] . An experienced stroke neurologist will use a transcranial Doppler ultrasound (TCD) machine (Companion III TCD   6 Neuroscience Journal Systems, Nicolet) to record PI, VMR, and middle cerebral artery (MCA) velocity, which is a measure of mean CBF velocity. Based on our experience and the literature reports we expect that over 80% of measurements will be completed through the adequate acoustical temporal bone window [48] . VMR assessments will be performed aer hyperventilation, the breath-holding test (BHT), and the acetazolamide (Diamox) test (ACT). Flow velocities and PIs will be measured in patients in a supine position in a quiet and breathing room air via transtemporal insonation of both MCA at a depth of 45-55 mm with a 2-MHz probes in a �xed position and averaged. e most powerful signal obtained during 10 cardiac cycles will be used to measure the mean �ow velocities (MFVs). Aer 2 minutes of hyperventilation, administration of the BHT, resting MFVs, and time of breath holding (BHTT) will be recorded. e BHT will be performed according to the Markus and Harrison procedure, in which patients are instructed to hold their breath in one inspiration aer a period of 4 minutes of normal breathing of room air. e ACT will be performed by intravenously injecting 10 mg/kg acetazolamide over 5 min. MCA MFVs are recorded before infusion and 15 minutes aer it has taken place [49, 50] . Blood pressure and heart rate are simultaneously monitored during the procedure; an increase in either of these parameters of >20% leads to excluding the data from analysis. All tests will be performed separately with breaks of 4 minutes between test administrations [51] [52] [53] . e following variables are automatically calculated from the tests: (1) Assessments of carotid intima-media thickness and atheromatous stenosis of the extracranial arteries will be performed according to previously validated criteria by colour-�ow B-mode Doppler ultrasonography (Loqic P6, GE Healthcare) [54] .
Ischemia-induced brachial artery �ow dilatation, which re�ects endothelial function, will be assessed. e procedure for this technique includes ultrasound scanning of the brachial artery at rest (baseline), as well as during hyperaemia, which will be induced by 5 minutes of in�ating and de�ating a sphygmomanometer cuff placed around the forearm distal to the ultrasound site [55] . Stress is created by increased blood �ow following transient ischemia and induces the release of nitric oxide (NO), which results in local arterial vasodilatation. Flow-mediated dilatation (FMD) is estimated as the percent increase in vessel diameter from baseline to maximum vasodilation, which occurs during hyperaemia [56] .
Twenty-four-hour ambulatory blood pressure (BP) monitoring (ABPM) will be performed using a portable noninvasive oscillometric and auscultatory device (Schiller MT-300). Measurements over a 24-hour period are recorded every 15 minutes during daytime hours (07.00 to 23.00) and every 30 minutes during nighttime hours (23.00 to 7.00). For recordings to be considered valid, a minimum of 15 daytime and 8 nighttime measurements is required. e mean 24-hour day and night systolic BP (SBP), diastolic BP (DBP), pulse pressure (PP), relative nocturnal dipping (SBP dipping), and mean heart rate will be calculated and recorded automatically. TCD and BP monitoring will be performed on the same day.
For all participants, serum cholesterol, HDL, LDL, triglycerides, glucose, HbA1c, uric acid, and albumin levels will be assessed. Evaluation of the endothelial and thrombocyte functions include: hsCRP, ICAM 1, PAI-1, thrombomodulin, homocysteine, d-dimers, �brinogen, IL-1, anticardiolipin antibody, vit.B12, MPV, PLT, and sP-selectin. ese functions are measured with commercially available ELISA kits according to the manufacturer's instructions.
Platelet aggregation in whole blood will be evaluated with multiple electrode platelet aggregometry (multiplate analyser, Dynabyte, Munich, Germany) [57] . Blood is collected in test tubes containing the anticoagulant hirudin (25 g/mL) (Sarstedt, Germany). We will use the following aggregation agonists: arachidonic acid (AA), adenosine diphosphate (ADP), and thrombin receptor agonist peptide (TRAP), all of which are supplied by the manufacturer of the aggregometer. Blood for testing will be collected in the morning from fasting patients, and assays will be performed within 2 h of blood collection. Assessments of aggregation include evaluation of the area under the curve (AUC) of the aggregation plot, the degree of aggregation (AGR), and aggregation velocity (VAGR). Aggregation is determined twice in each sample, and the mean value is calculated if the two values differ by less than 10%. In the event that the values differ by 10% or more, the aggregation assays will be repeated.
Other Clinical Indicators (Baseline Visit).
Retinal vessels can be visualised noninvasively and will be used to assess systemic vascular damage. e presence of retinal vessel abnormalities will be analysed using digitised fundus transparencies with a semiautomated system [58] . Aer dilation of the pupils with 1% tropicamide, retinal photographs centred on the optic disc will be taken off each eye using a nonmydriatic digital camera. e calibre of retinal arterioles and venules is measured from the photograph using a validated computer-assisted method. e retinal arteriole/venule ratio (AVR) is calculated by dividing the mean arteriolar calibre by the mean venular calibre.
2.3.7.
Followup. Two years aer taking the baseline measurements, all participants will be contacted for prospective assessment of potential outcome events using the same instruments as at baseline visit including neurological (mRS, NIHSS, the Barthel Scale, UPDRS, and the Berg Balance Scale), neuropsychological (full battery of previously described tests), and radiological (MRI) examinations. Recurrent strokes and/or death due to cardiovascular reasons will be noted. If these assessments cannot be administered in person, researchers will contact the patient or his/her caregiver via phone. e patient's functional state will be assessed according to the mRS in cases requiring a phone call. 
Statistical Analysis
Recent studies demonstrated a high rate of WMLs progression (36%-75%/3 years) detected with repeated MRI even in otherwise healthy older populations [59] . Advanced age, WML severity, and presence of lacunar brain infarcts at baseline were strongly associated with lesion progression independent of other cardiovascular risk factors [60] . Based on study inclusions criteria which required documented WMLs at baseline MRI, it is expected that our study population has a relatively high degree of WMLs and high risk of progression. A sample size analysis was performed to determine the minimum number of patients required. e minimum effect size was 10%. Accounting for a maximum estimated 10% loss to followup, a total of 150 patients with CVSD and 50 from CG will be required to test the null hypothesis with an value of 0.05 and a power of 0.8. Based on the hospital data set and estimated annual number of patients admitted due to CSVD we decided to establish unequal CSVD groups: with lacunar stroke ( ), vascular dementia ( ), deep hemorrhagic strokes ( ), and vascular parkinsonism ( ). Student's -test and chi-squared tests will be used to make between-groups comparisons of continuous and categorical variables. Log-transformations will be used to correct for nonnormality of the data. Demographic data, vascular risk pro�les, and hemodynamic data of the study groups will be compared by Student's -test and ANOVA. e degree of neurological improvement or deterioration will be assessed via comparing the baseline and followup results. Pearson's correlation coefficients and ANOVA will be used to correlate haemodynamic data and neurological status at baseline and followup time points. e association between WML severity and haemodynamic and haemostatic data and cognitive, motor, and balance function will be assessed using linear regression models. Changes in MRI parameters neuropsychological and neurological data between the 2 time points will be assessed via paired -tests for parametric data or the Wilcoxon signed-rank test for nonparametric data. Percent difference for each of the parameters will be calculated. Multivariate analysis that is adjusted for potentially confounding subject-relevant variables (age, sex, and vascular risk factor pro�le) will be performed to determine which haemostatic and haemodynamic factors are most useful measures of association to predict changes in neurological status, neuropsychological function, and severity of WMLs at baseline and followup.
Summary
Despite conceivable advances in our understanding of the natural history of WMLs over the past few years, several research questions need to be resolved. Numerous studies have shown that WMLs are related to vascular risk factors. e exact diagnosis of CSVD is, however, still not well known and requires systematic evaluation of potentially relevant clinical and other phenotypic features. It has been suggested that a prothrombotic state and endothelial activation are possible causal factors but recent neuropathology study did not con�rm that relation [61] [62] [63] . It is also unknown how endothelial activation and likely consequent dysfunction mediate its effect. e "gold standard" for con�rming the clinical diagnosis of vascular parkinsonism and dementia is also not established, and the literature reports that the associations between WMLs and cognitive and motor decline are rather weak [64] . e "optimal" treatment with regard to primary and secondary prevention of CSVD is not clear [65] . e SHEF-CSVD study is a large, prospective study that examines the signi�cance of haemodynamic and haemostatic prognostic factors and their course over time in CSVD. To the best of our knowledge, no prospective cohort studies that investigate haemodynamic and haemostatic factors in differing manifestations of CSVD have been performed. Strengths of the SHEF-CSVD study include the prospective nature of the study; two protocols will be completed at baseline and 24-month followup. Additionally, all of these protocols will take place in one research centre, and the same researchers will collect all the data for the study using the same scanner. Furthermore, the tests and radiologic protocols chosen for this study are widely accepted and have been proven to be speci�c and sensitive in populations with WMLs. Still, some methodological issues should be considered. First, there is a possibility of selection bias. Second, we use an MRI semiquantitative visual measurement tool, which gives less precise estimates of lesion progression than a volumetric measurement. Larger number of participants with wider range of population groups and the ability to compare results among different sites in multicentre trial would potentially increase the generalizability of the study but it was not economically nor logistically feasible for our study group. e study has, however, the potential to unravel the functional and neuropsychological consequences of WMLs progression with regard to different hemostatic and hemodynamic factors which could serve as potential therapeutic targets. With the aging of the society, the importance of early diagnosis and prophylactic treatment of CSVD should be greatly noticed.
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